Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 560 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 560 shares of Oruka Therapeutics stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $95.71, for a total value of $53,597.60. Following the sale, the senior vice president directly owned 14,752 shares in the company, valued at $1,411,913.92. The trade was a 3.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.23, for a total value of $872,403.57.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00.
• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The stock was sold at an average price of $84.63, for a total transaction of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.95, for a total transaction of $128,467.65.

Oruka Therapeutics Trading Down 3.9%

ORKA traded down $3.73 on Tuesday, reaching $92.20. The company had a trading volume of 784,617 shares, compared to its average volume of 741,278. The company has a market capitalization of $6.10 billion, a P/E ratio of -45.42 and a beta of -0.34. The company has a fifty day moving average of $95.87 and a 200-day moving average of $72.78. Oruka Therapeutics, Inc. has a one year low of $14.66 and a one year high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Research analysts predict that Oruka Therapeutics, Inc. will post -2.42 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Engineers Gate Manager LP bought a new position in shares of Oruka Therapeutics in the second quarter valued at $350,000. Arizona State Retirement System grew its holdings in shares of Oruka Therapeutics by 45.0% in the 2nd quarter. Arizona State Retirement System now owns 8,671 shares of the company’s stock worth $825,000 after acquiring an additional 2,691 shares during the last quarter. Nykredit A S acquired a new position in shares of Oruka Therapeutics in the 2nd quarter worth $29,000. Braidwell LP acquired a new stake in shares of Oruka Therapeutics during the second quarter worth $26,473,000. Finally, Natural Investments LLC acquired a new stake in shares of Oruka Therapeutics during the second quarter worth $202,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

ORKA has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Wedbush reissued an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Guggenheim reaffirmed a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Finally, Mizuho set a $120.00 target price on Oruka Therapeutics in a report on Thursday, September 3rd. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $133.00.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.